JP2023537002A5 - - Google Patents
Info
- Publication number
- JP2023537002A5 JP2023537002A5 JP2023507973A JP2023507973A JP2023537002A5 JP 2023537002 A5 JP2023537002 A5 JP 2023537002A5 JP 2023507973 A JP2023507973 A JP 2023507973A JP 2023507973 A JP2023507973 A JP 2023507973A JP 2023537002 A5 JP2023537002 A5 JP 2023537002A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- sequence
- antigen
- antibody
- binding fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025250936A JP2026034608A (ja) | 2020-08-06 | 2025-12-15 | 抗クローディン１８．２多重特異性抗体及びそれらの使用 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063061895P | 2020-08-06 | 2020-08-06 | |
| US63/061,895 | 2020-08-06 | ||
| US202063074582P | 2020-09-04 | 2020-09-04 | |
| US63/074,582 | 2020-09-04 | ||
| US202163144657P | 2021-02-02 | 2021-02-02 | |
| US63/144,657 | 2021-02-02 | ||
| PCT/US2021/044801 WO2022032004A2 (en) | 2020-08-06 | 2021-08-05 | Anti-claudin 18.2 multi-specific antibodies and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025250936A Division JP2026034608A (ja) | 2020-08-06 | 2025-12-15 | 抗クローディン１８．２多重特異性抗体及びそれらの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023537002A JP2023537002A (ja) | 2023-08-30 |
| JP2023537002A5 true JP2023537002A5 (enExample) | 2024-08-13 |
| JP7792395B2 JP7792395B2 (ja) | 2025-12-25 |
Family
ID=80117669
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023507973A Active JP7792395B2 (ja) | 2020-08-06 | 2021-08-05 | 抗クローディン１８．２多重特異性抗体及びそれらの使用 |
| JP2025250936A Pending JP2026034608A (ja) | 2020-08-06 | 2025-12-15 | 抗クローディン１８．２多重特異性抗体及びそれらの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025250936A Pending JP2026034608A (ja) | 2020-08-06 | 2025-12-15 | 抗クローディン１８．２多重特異性抗体及びそれらの使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20230279152A1 (enExample) |
| EP (1) | EP4192879A4 (enExample) |
| JP (2) | JP7792395B2 (enExample) |
| KR (1) | KR20230070203A (enExample) |
| WO (2) | WO2022032004A2 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020023702A1 (en) | 2018-07-25 | 2020-01-30 | AskGene Pharma, Inc. | Novel il-21 prodrugs and methods of use thereof |
| JP7137696B2 (ja) | 2019-05-14 | 2022-09-14 | プロヴェンション・バイオ・インコーポレイテッド | １型糖尿病を予防するための方法および組成物 |
| AU2021205981A1 (en) | 2020-01-11 | 2022-07-14 | AskGene Pharma, Inc. | Novel masked cytokines and methods of use thereof |
| KR20230092863A (ko) | 2020-06-11 | 2023-06-26 | 프로벤션 바이오, 인코포레이티드 | 제1형 당뇨병을 예방하기 위한 방법 및 조성물 |
| MX2023013851A (es) | 2021-05-24 | 2023-12-08 | Provention Bio Inc | Metodos para el tratamiento de diabetes tipo 1. |
| US20250158109A1 (en) | 2022-05-31 | 2025-05-15 | Lg Energy Solution, Ltd. | Composite solid electrolyte for lithium secondary battery and preparation method thereof |
| CN119101162A (zh) * | 2023-06-07 | 2024-12-10 | 江苏奥赛康生物医药有限公司 | 一种抗cldn18_2的抗体及体外诊断试剂盒 |
| WO2024250437A1 (en) * | 2023-06-08 | 2024-12-12 | Antengene (Hangzhou) Biologics Co., Ltd. | Anti-cldn18.2 antibodies and diagnostic uses thereof |
| CN119874911B (zh) * | 2025-01-02 | 2025-12-30 | 上海以岭药业有限公司 | 靶向cldn18.2的抗原结合蛋白及其应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2436397B1 (en) * | 2009-05-29 | 2017-05-10 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical composition containing antagonist of egf family ligand as component |
| WO2016054598A2 (en) * | 2014-10-03 | 2016-04-07 | Massachusetts Institute Of Technology | Antibodies that bind ebola glycoprotein and uses thereof |
| EP3302563A1 (en) * | 2015-05-29 | 2018-04-11 | H. Hoffnabb-La Roche Ag | Humanized anti-ebola virus glycoprotein antibodies and methods of use |
| CA2990398A1 (en) * | 2015-06-23 | 2016-12-29 | Bayer Pharma Aktiengesellschaft | Antibody drug conjugates of kinesin spindel protein (ksp) inhibitors with anti-cd123-antibodies |
| CN116178554B (zh) * | 2018-05-18 | 2025-09-09 | 礼新医药科技(上海)有限公司 | 抗密蛋白18.2抗体及其用途 |
| EP3808376A4 (en) * | 2018-06-17 | 2021-09-01 | L&L Biopharma Co., Ltd. | CLDN18.2 ANTIBODY, BISPECIFIC ANTIBODY, ADC AND CAR, AND APPLICATIONS THEREOF |
| WO2020023679A1 (en) * | 2018-07-25 | 2020-01-30 | Accurus Biosciences, Inc. | Novel cldn 18.2-specific monoclonal antibodies and methods of use thereof |
| BR112021002032A2 (pt) | 2018-08-03 | 2021-07-20 | Amgen Research (Munich) Gmbh | construtos de anticorpos para cldn18.2 e cd3 |
| US10522488B1 (en) * | 2018-10-31 | 2019-12-31 | Taiwan Semiconductor Manufacturing Company, Ltd. | Patterning polymer layer to reduce stress |
| CN109762067B (zh) * | 2019-01-17 | 2020-02-28 | 北京天广实生物技术股份有限公司 | 结合人Claudin 18.2的抗体及其用途 |
-
2021
- 2021-08-05 WO PCT/US2021/044801 patent/WO2022032004A2/en not_active Ceased
- 2021-08-05 WO PCT/US2021/044800 patent/WO2022032003A2/en not_active Ceased
- 2021-08-05 JP JP2023507973A patent/JP7792395B2/ja active Active
- 2021-08-05 US US18/019,728 patent/US20230279152A1/en active Pending
- 2021-08-05 KR KR1020237007877A patent/KR20230070203A/ko active Pending
- 2021-08-05 EP EP21853256.2A patent/EP4192879A4/en active Pending
-
2025
- 2025-12-15 JP JP2025250936A patent/JP2026034608A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Paul et al. | Cancer therapy with antibodies | |
| US12384850B2 (en) | Guidance and navigation control proteins and method of making and using thereof | |
| Xu et al. | Retargeting T cells to GD2 pentasaccharide on human tumors using bispecific humanized antibody | |
| US12029761B2 (en) | Guidance and Navigation Control proteins and method of making and using thereof | |
| Zekri et al. | An optimized IgG-based B7-H3xCD3 bispecific antibody for treatment of gastrointestinal cancers | |
| JP2022541435A5 (enExample) | ||
| JP2022546572A5 (enExample) | ||
| RU2017145150A (ru) | Антитело против pdl-1, его фармацевтическая композиция и применение | |
| JP2022525435A5 (enExample) | ||
| JP2024530166A5 (enExample) | ||
| Guo et al. | Revolutionizing cancer immunotherapy: unleashing the potential of bispecific antibodies for targeted treatment | |
| CN114634569A (zh) | 高亲和力b7-h6抗体和抗体片段 | |
| JP2023523584A5 (enExample) | ||
| JP2020523029A5 (enExample) | ||
| Wang et al. | An optimal antitumor response by a novel CEA/CD3 bispecific antibody for colorectal cancers | |
| JP2025508066A (ja) | 目的としたｔ細胞活性化のためのｃｄ２８二重特異性抗体 | |
| CN111065409A (zh) | Strep-tag特异性结合蛋白及其用途 | |
| JP7592712B2 (ja) | ガイダンス及びナビゲーションコントロールタンパク質、その製造方法及び使用方法 | |
| Holliger et al. | Engineering antibodies for the clinic | |
| US20240141043A1 (en) | Bispecific antibody that binds to cd3 and a fluorophore | |
| Jachimowicz et al. | Multi-specific antibodies for cancer immunotherapy | |
| WO2022093694A1 (en) | Polypeptides targeting hpv peptide-mhc complexes and methods of use thereof | |
| JP2024540863A5 (enExample) | ||
| Elloumi et al. | Monoclonal antibodies as cancer therapeutics | |
| WO2025067496A1 (zh) | 靶向baff-r的全人源抗体、car-t细胞及其应用 |